Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 3
1977 4
1978 1
1979 2
1981 2
1982 1
1983 3
1984 4
1985 2
1986 2
1987 3
1988 6
1989 5
1990 4
1991 2
1992 3
1993 4
1994 1
1995 3
1996 3
1997 8
1998 4
1999 6
2000 6
2001 9
2002 6
2003 6
2004 5
2005 10
2006 6
2007 6
2008 6
2009 5
2010 3
2011 7
2012 8
2013 20
2014 13
2015 11
2016 8
2017 5
2018 5
2019 12
2020 12
2021 10
2022 10
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Results by year

Filters applied: . Clear all
Page 1
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, Bredeek F, García Deltoro M, Swindells S, Andrade-Villanueva JF, Wong A, Khuong-Josses MA, Van Solingen-Ristea R, van Eygen V, Crauwels H, Ford S, Talarico C, Benn P, Wang Y, Hudson KJ, Chounta V, Cutrell A, Patel P, Shaefer M, Margolis DA, Smith KY, Vanveggel S, Spreen W. Overton ET, et al. Among authors: benn p. Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9. Lancet. 2021. PMID: 33308425 Clinical Trial.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, Hermida AO, Thalme A, Belonosova E, Ajana F, Benn PD, Wang Y, Hudson KJ, Español CM, Ford SL, Crauwels H, Margolis DA, Talarico CL, Smith KY, van Eygen V, Van Solingen-Ristea R, Vanveggel S, Spreen WR. Jaeger H, et al. Among authors: benn pd. Lancet HIV. 2021 Nov;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5. Epub 2021 Oct 11. Lancet HIV. 2021. PMID: 34648734 Clinical Trial.
The origins of aneuploidy research consortium.
Benn P, Cuckle H, Pergament E. Benn P, et al. Prenat Diagn. 2021 Apr;41(5):642-646. doi: 10.1002/pd.5934. Epub 2021 Mar 22. Prenat Diagn. 2021. PMID: 33720446
Non-invasive prenatal screening: A 20-year experience in Italy.
Palka C, Guanciali-Franchi P, Morizio E, Alfonsi M, Papponetti M, Sabbatinelli G, Palka G, Calabrese G, Benn P. Palka C, et al. Among authors: benn p. Eur J Obstet Gynecol Reprod Biol X. 2019 May 18;3:100050. doi: 10.1016/j.eurox.2019.100050. eCollection 2019 Jul. Eur J Obstet Gynecol Reprod Biol X. 2019. PMID: 31403132 Free PMC article. Review.
HIV and postexposure prophylaxis.
Benn P, Fisher M. Benn P, et al. Clin Med (Lond). 2008 Jun;8(3):319-22. doi: 10.7861/clinmedicine.8-3-319. Clin Med (Lond). 2008. PMID: 18624047 Free PMC article. Review. No abstract available.
252 results